{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2017"],"condition":["Cancer; including Breast, Ovarian, Colorectal, Metastatic colorectal(those investigated as part of previous trials using Enadenotucirev).","Cáncer; Incluyendo cáncer de mama, ovárico, colorrectal, colorectal metastásico (los investigados como parte de ensayos previos utilizando Enadenotucirev)."],"disease":["Cancer; Including Breast, Ovarian, Colorectal, Metastatic Colorectal(those Investigated As Part Of Previous Trials Using Enadenotucirev).","Cáncer; Incluyendo Cáncer De Mama, Ovárico, Colorrectal, Colorectal Metastásico (los Investigados Como Parte De Ensayos Previos Utilizando Enadenotucirev)."],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2536439"],"location":["Belgium","United States","United Kingdom","Spain"],"study_start_month":["6"],"keyword":["Enadenotucirev"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A multicentre observational study for the long term follow up of subjects that have been treated with enadenotucirev during interventional clinical trial","description":"Primary objectives: To follow up subjects that have received enadenotucirev during a clinical trial to assess their long term well-being","dates":{"creation":"2017-06-15"},"accession":"2536439","cross_references":{"EU Clinical Trials Register":["2016-004777-40"]}}